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Vascular endothelial growth factor (VEGF) regulates key functions of the endothelium 
such as angiogenesis or vessel repair in processes involving endothelial Nitric Oxide Synthase 
(eNOS) activation. On the other hand, one of the effector kinases that become activated in 
endothelial cells upon VEGF treatment is Protein Kinase D (PKD). We show herein that PKD 
uses eNOS as substrate leading to its activation with the concomitant increased ·NO 
synthesis. Using mass spectrometry, we show that the purified active kinase specifically 
phosphorylates recombinant eNOS on Ser1179. Treatment of endothelial cells with VEGF or 
PDBu activates PKD and increases eNOS Ser1179 phosphorylation. In addition, 
pharmacological inhibition of PKD and gene silencing of both PKD1 and PKD2 abrogate 
VEGF signaling, resulting in a clear diminished migration of endothelial cells in a wound-
healing assay. Finally, inhibition of PKD in mice results in an almost complete disappearance 
of the VEGF-induced vasodilatation as monitored through the determination of the diameter 
of the carotid artery. Hence, our data indicate that PKD is a novel regulatory kinase of eNOS 




























Vascular endothelial growth factor (VEFG) is a key physiological regulator of both 
vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in 
the adult (angiogenesis). VEGF is mainly secreted from mesenchymal, stromal and epithelial 
sources to act on endothelial cells in both arteries and veins and its receptors are 
transmembrane proteins that belong to the receptor tyrosine kinase family (Ferrara et al., 
2003; Ho and Kuo, 2007; Olsson et al., 2006). The angiogenic effects of VEGF are primarily 
mediated by VEGF receptor-2 (VEGFR2) (Ho and Kuo, 2007). Upon VEGF binding to 
endothelial cells, VEGFR2 undergoes dimerization and tyrosine kinase autophosphorylation, 
which, in turn, activates various signaling cascades (Byrne et al., 2005). The best 
characterized action of VEGF on endothelial cells is the ability to promote their growth, 
stimulation of DNA synthesis and proliferation (Parenti et al., 1998). In addition, VEGF is 
also a survival factor for endothelial cells in vitro, preventing apoptosis induced by serum 
starvation in a process mediated, at least partially, by the PI3K/Akt pathway (Fujio and 
Walsh, 1999; Gerber et al., 1998a; Gerber et al., 1998b). Furthermore, a constitutively active 
Akt was sufficient to promote survival of serum-starved endothelial cells (Gerber et al., 
1998b).  
At present, two isoforms of the PKD family, PKD1 and PKD2, have emerged as novel 
crucial molecular players not only in VEGF signaling and angiogenesis but also in other 
important signaling pathways in the cardiovascular system (Evans and Zachary, 2011; Ha and 
Jin, 2009). It has also been confirmed that VEGF-mediated PKD activation in endothelial 
cells promotes both proliferation and migration (Hao et al., 2009; Qin et al., 2006; Wong and 
Jin, 2005), with PKD activation involving PKC-mediated PKD phosphorylation (Zugaza et 
al., 1996). Although PKD activity functionally seems to regulate migration, proliferation and 
apoptosis in endothelial cells, the identification of PKD substrates in endothelial cells has 
remained elusive (Avkiran et al., 2008). 
As early as 1993, Brock and coworkers reported that the vasodilatation induced by 
VEGF on endothelial cells was dependent on the activity of endothelial Nitric Oxide Synthase 
(eNOS), since preincubation with eNOS inhibitors such as L-NMMA blocked the relaxation 
of coronary arteries induced by VEGF (Ku et al., 1993). Subsequently other reports showed 
that systemic administration of eNOS inhibitors to rabbits bearing a corneal implant blocked 
the migration of endothelial cells induced by VEGF (Ziche et al., 1997). In addition, 
pharmacological doses of VEGF are known to stimulate endothelial nitric oxide (·NO) 
























2005) whereas inhibition of VEGFR2 using a specific antibody rapidly increases blood 
pressure in mice (Facemire et al., 2009). In humans, VEGF also maintains a normal 
endothelial control of vasomotor tone since injection of a monoclonal anti-VEGF antibody 
into the brachial artery inactivates circulating VEGF hence decreasing endothelium-dependent 
vasodilatation within 15 min (Thijs et al., 2013). 
VEGF-dependent phosphorylation of eNOS Ser 1179 and the subsequent boost in ·NO 
synthesis has been for some time considered to be mediated directly by activated Akt (Protein 
Kinase B) (Fleming, 2010; Forstermann and Sessa, 2012; Michel and Vanhoutte, 2010). 
However, it is becoming clear that Akt is not the only activated kinase to target eNOS 
Ser1179 upon VEGF treatment of endothelial cells. Expression of a dominant negative Akt 
mutant in bovine endothelial cells only partially inhibits phosphorylation of eNOS Ser1179 
induced by VEGF (Boo et al., 2002). Furthermore, a very evident phosphorylation on eNOS 
Ser1179 could still be observed in lung endothelial cells derived from Akt knock-out mice 
injected with VEGF (Schleicher et al., 2009).  
Therefore, given that VEGF-mediated actions proceed through the activation of various 
protein kinases, including PKD, it is feasible that PKD could be involved in the 
phosphorylation-dependent activation of eNOS induced by this growth factor. Supporting this 
idea, Hao and coworkers showed in a recent report that an antibody recognizing 
phosphorylated PKD substrates labeled prominently a band of approximately 135 kDa in 
human endothelial cells treated with VEGF. Importantly, the intensity of this band decreased 
partially after PKD2 silencing (Hao et al., 2009). Herein, we have analyzed the possible 
participation of PKD in eNOS phosphorylation and activation. We show that, indeed, eNOS is 
a PKD substrate both in vitro and in transfected cells. In addition, we show that PKD1 and 
PKD2 can associate to eNOS in cells and also that silencing of these PKD isoforms abrogates 
eNOS-mediated wound-healing process in VEGF-treated endothelial cells. Finally, we also 
report that mice injected in the carotid artery with a PKD inhibitor display a clearly 
diminished response towards VEGF-mediated vasodilatation, a process that requires eNOS 
activation. In summary, we have identified eNOS as the first PKD substrate specific of 
endothelial cells and shed light on a novel regulatory mechanism of eNOS activity with 





























eNOS is a novel substrate of PKD1 
Since VEGF activates PKD isoforms in endothelial cells we wondered whether PKD could be 
using eNOS as a direct substrate in the endothelium and the possible functional outcome. 
Given that VEGF triggers and array of signaling pathways in cultured endothelial cells, we 
decided to initially perform in vitro kinase assays using recombinant proteins. We incubated 
recombinant bovine eNOS with purified active catalytic domain of PKD1 fused to GST 
(PKD1-cat active) in the presence of ATP. In order to identify phosphorylated residues in 
eNOS, the product of the in vitro kinase reaction was digested with trypsin and subjected to 
HPLC and peptide fragmentation by MALDI TOF/TOF (Fig. 1A). Several hundred eNOS-
derived peptides were obtained, but only one significant phosphopeptide was identified. De 
novo sequencing of an eluted tryptic peptide with a mass of 1174,502 Da revealed that it 
corresponded to sequence TQpSFSLQER (residues T1177-R1185 of bovine eNOS) and the 
phosphorylated residue was assigned to the Ser residue present at the third position (pS; b3 in 
Fig. 1A). Therefore, eNOS Ser1179 located within the C-terminus was the serine 
phosphorylated by PKD1 in vitro. In order to corroborate the mass spectrometry data, we used 
a commercially available phospho-specific antibody recognizing this phospho-site (eNOS-
pSer1179) and performed an in vitro kinase assay as above followed by immunoblot analysis. 
The eNOS-pSer1179 antibody only detected phosphorylated eNOS when pre-incubated with 
active catalytic domain of PKD1 in the presence of ATP (Fig. 1B). 
 
Expression of eNOS, PKD1 and PKD2 in endothelial cells 
To validate our in vitro data, we further investigated whether in BAEC (Bovine Aortic 
Endothelial Cells) endogenous eNOS would become phosphorylated by ectopically expressed 
PKD. Transfection of GFP-tagged wild-type PKD1 or PKD2 into BAEC led to a robust 
increase in endogenous eNOS phosphorylation on Ser1179 (Fig. 2A). Detection of a high 
degree of overexpressed PKD1 and PKD2 autophosphorylation using a phosphospecific 
antibody (PKD-pSer916), that reflects the activation state of both isoforms (Matthews et al., 
2000), indicated that they were active when transfected into BAEC. In addition, the increased 
appearance of VASP (Vasodilator-stimulated Phosphoprotein) phosphorylated at Ser239, a 
read-out for ·NO release (Sartoretto et al., 2009), suggested that eNOS phosphorylation on 
Ser1179 mediated by PKD1 and PKD2 results in enzymatic activation and increased ·NO 
synthesis. BAEC presented a basal level of eNOS Ser1179 phosphorylation that indicated this 
























including PKD. To check PKD content in BAEC, we performed immunoblot analysis and 
detected bands corresponding to both PKD1 and PKD2 isoforms (Fig. 2B). Since little is 
known about endogenous PKD expression in endothelium, we also examined the presence of 
PKD in frozen tissue samples of mouse carotid arteries and its possible colocalization with 
eNOS by confocal immunomicroscopy. Figure 2C shows that eNOS was present in the 
monolayer of endothelial cells whereas PKD signal was detected in tunica media and also in 
endothelium, where it colocalized with eNOS. 
 
PKD-mediated eNOS Ser1179 phosphorylation results in increased ·NO synthesis 
Next, we continued exploring eNOS phosphorylation on Ser1179 by PKD using an eNOS 
construct where this serine had been mutated. For that purpose, we used HEK293T cells 
cotransfected with wild-type eNOS or the non-phosphorylatable mutant eNOS-Ser1179Ala 
(eNOSSA) together with GFP-tagged wild-type PKD1 or PKD2 (PKD1wt and PKD2wt) (Fig. 
3A). As shown in the figure, although there is a basal phosphorylation of wild-type eNOS on 
Ser1179, transfection of both PKD1 and PKD2 increases this phosphorylation approximately 
two-fold. As expected, when the phosphorylatable eNOS Ser1179 was mutated into Ala, no 
phosphorylation could be detected either in the presence or absence of transfected PKD1 or 
PKD2. In order to further analyze the contribution of PKD activity to the phosphorylation 
Ser1179 within eNOS, HEK293T cells were cotransfected with both wild-type eNOS and 
eNOSSA constructs together with GFP-tagged PKD1 wild-type (PKDwt), or constitutively 
active (PKD1ca) or kinase-inactive (PKD1ki) mutants (Fig. 3B). The increase on eNOS 
Ser1179 phosphorylation was more significant when wild-type or constitutively active PKD1 
were overexpressed and nonexistent when the kinase-inactive mutant was used (Fig. 3B), 
indicating that phosphorylation of this site in eNOS is indeed regulated by PKD activity. In 
these cells, Ser1179 phosphorylation signal was only found after wild-type eNOS 
transfection, and accordingly, no signal was detected when eNOS-Ser1179Ala mutant was 
used. 
It has been previously reported that, mechanistically, eNOS phosphorylation on 
Ser1179 enhances the rate of electron flux from the reductase to the oxygenase domain of the 
protein and reduces the relative calcium requirement for the enzyme, thus increasing ·NO 
synthesis (McCabe et al., 2000). In order to analyze the effect of PKD phosphorylation on 
eNOS activity, COS-7 cells were transfected with wild-type eNOS or its non-
phosphorylatable Ser1179Ala mutant in the presence or absence of PKD1wt, PKD1ca or 
























DA (4,5-Diaminofluorescein diacetate) (Fig. 3C) and also as [14C]-L-Citrulline formation 
when [14C]-L-Arginine was used as a substrate (Fig. 3D). As a positive control, we also 
transfected COS-7 cells with iNOS, since this isoform releases large amounts of ·NO and its 
activity is not dependent on the intracellular calcium concentrations. Interestingly, the non-
phosphorylatable eNOS mutant (eNOSSA), when transfected alone or together with PKD1wt, 
was unable to release detectable ·NO levels in the absence of added calcium ionophores. In 
contrast, the ·NO-releasing activity of transfected wild-type eNOS was low but increased 
significantly when cotransfected with PKD1wt. This effect was slightly but significantly 
further enhanced by activating PKD1 with PDBu (phorbol 12, 13-dibutyrate), and was 
blocked after incubating the cells with the eNOS inhibitor L-NAME (Fig. 3C). Likewise, the 
conversion of [14C]-L-Arg into [14C]-L-Cit in lysates obtained from COS-7 cells transfected 
with wild-type eNOS augmented significantly when cotransfected with PKD1wt, PKD2wt or 
PKD1ca. Finally, even when wild-type eNOS was cotransfected with PKD1ca the amount of 
[14C]-L-Cit formed was significantly diminished when the eNOS inhibitor L-NAME was 
present (Fig. 3D). Thus, our data indicate not only that PKD1 phosphorylation of eNOS 
activates ·NO synthesis but also that phosphorylation displaces the calcium/calmodulin-
binding curve towards lower Ca2+ concentrations. Hence, PKD1 phosphorylation of eNOS 
activates the enzyme and further confirms the proposal that phosphorylation of Ser1179 
mediates the calcium-independent activation of eNOS (Dimmeler et al., 1999; Fulton et al., 
1999; McCabe et al., 2000). 
 
PKD1 and eNOS form a complex in mammalian cells 
We next analyzed whether PKD1 or PKD2 were able to associate with eNOS. For that 
purpose, we transfected HEK293T cells with full-length wild-type eNOS or a mutant that 
lacked the C-terminus (eNOSΔ27) including the phosphorylation site, together with wild-type 
GFP-PKD1 and GFP-PKD2 (PKD1 or PKD2). Two days after transfection PKD was 
immunoprecipitated from total lysates using anti-GFP antibody and the presence of eNOS in 
the immunocomplexes was assessed by detecting the signal for eNOS by immunoblot (Fig. 
4A). Our results showed that wild-type eNOS associates with both PKD isoforms, and that the 
eNOS phosphorylation site was not involved in the association because an eNOS mutant 
lacking the C-terminus still associated with PKD1 and PKD2. Next, we also examined which 
PKD1 domains could be mediating this association and whether PKD activity could affect it 
using GFP-PKD1wt, the constitutively active mutant (PKD1ca), and two mutants in which the 
























(PKD1ΔCRD and PKD1ΔPH, respectively) (Fig. 4B). These constructs were cotransfected with 
wild-type eNOS in the presence or absence of PDBu treatment to activate the kinase. Then, 
lysates were immunoprecipitated with an anti-GFP antibody. As shown in the figure, GFP by 
itself could not associate to eNOS (lanes 1 and 2) whereas all the PKD constructs tested were 
able to associate with full-length eNOS independently of PDBu treatment. Hence, the 
association between the eNOS and PKD1 is not mediated by the CRD or the PH domains and 
does not require the activation of the kinase or the presence of the phosphorylatable eNOS 
Ser1179 residue. 
In order to complement our studies we examined which region of eNOS could be 
mediating this association. HEK293T cells were cotransfected with PKD1wt, or the empty 
vector, together with different eNOS constructs: full-length wild-type eNOS, the C-terminus 
truncated mutant (eNOS Δ27), the NADPH binding domain (NADPH, aa 988-1205) or the 
heme-oxygenase domain (HEME, aa 1-521) (Fig. 4C). Two days after transfection and before 
lysis, cells were left untreated or treated with PDBu for 15 min to activate PKD1. Then, 
lysates were immunoprecipitated with an anti-eNOS polyclonal antibody and PKD and eNOS 
were detected. PKD activation by PDBu, although increased eNOS phosphorylation, did not 
potentiate the formation of eNOS/PKD1 complexes. PKD coimmunoprecipitation was 
observed with full-length eNOS and with its C-terminus mutant Δ27 but was hardly 
detectable with the NADPH-binding domains of eNOS or undetectable with the isolated 
heme-oxygenase. Thus, our results indicate that eNOS associates to PKD1 through residues 
comprised between the CaM binding sequence and the FAD/FMN modules. 
 
Stimuli that activate PKD in endothelial cells induce eNOS Ser1179 phosphorylation 
and redistribute both proteins 
The fact that VEGF treatment of BAEC leads to the activation of PKD (Wong and Jin, 2005) 
led us to explore VEGF-induced eNOS phosphorylation. We examined the activation of 
endothelial PKD through the addition of PDBu for 15 min (Fig. 5A) or VEGF for 30 min 
(Fig. 5B) and found a substantial increase in PKD Ser916 phosphorylation of approximately 
two-fold with both stimuli. Under identical circumstances, eNOS Ser1179 phosphorylation is 
significantly augmented (Fig. 5A and 5B) hence indicating that endogenous PKD isoforms 
might be responsible, at least in part, for the observed eNOS phosphorylation at this position. 
Furthermore, the vasodilator peptide bradykinin also rapidly induced PKD activation with the 
concomitant eNOS Ser1179 phosphorylation (Fig. S1). Importantly, the time course of 
























to 30 min assayed (Fig. 5C). Thus, these results indicate a correlation between endogenous 
PKD activation in endothelial cells and eNOS phosphorylation on Ser1179. 
It has been described that in non-stimulated endothelial cells eNOS targets to specific 
intracellular domains, including the Golgi apparatus and cholesterol/sphingolipid-rich 
microdomains of the plasma membrane (caveolae) and that upon stimulation its localization 
changes from membranous compartments to the cytosol, being this translocation important for 
activation-inactivation of the enzyme (Forstermann and Sessa, 2012; Michel and Vanhoutte, 
2010). On the other hand PKD is mainly cytosolic, showing some association to intracellular 
compartments, including the Golgi apparatus, in unstimulated cells and it can rapidly 
translocate to different subcellular compartments depending on the cellular context and 
stimulation conditions (Rozengurt, 2011). Here, we analyzed the subcellular localization of 
endogenous eNOS in BAEC transfected with GFP-tagged PKD1 by confocal microscopy. 
Transfected BAEC were left untreated or stimulated with VEGF for 15 min, then fixed and 
immunostained using an anti-eNOS antibody. As shown in Figure 5D, in resting cells both 
eNOS and PKD1 were excluded from the cell nucleus and enriched in endomembranes and 
perinuclear areas of the cell (very likely the Golgi apparatus) where a high degree of 
colocalization could be observed. After VEGF stimulation both proteins suffered a bulk 
translocation, with their subcellular distribution becoming more cytoplasmic and less 
condensed in perinuclear areas. No apparent plasma membrane localization of eNOS could be 
detected in agreement with the previously reported cytoplasmic immunolocalization of 
activated Ser1179 phosphorylated eNOS (Fulton et al., 2002). In the case of PKD1, some 
translocation to certain plasma membrane regions could be observed as well. This subcellular 
redistribution is in agreement with previous studies in HUVEC that reported that, whereas in 
the absence of VEGF stimulation PKD1 was almost completely absent from the plasma 
membrane, a short stimulation of endothelial cells with VEGF induced PKD1 translocation to 
plasma membrane protrusions, likely lamellipodia (di Blasio et al., 2010). Similar results were 
obtained when GFP-PKD2 was transfected (data not shown). 
 
PKD inhibition or gene silencing markedly diminishes migration of BAEC 
We next examined the role of endogenous PKD in BAEC migration, an eNOS-dependent 
process that plays key roles in angiogenesis (Borniquel et al., 2010; Lopez-Rivera et al., 
2005). For that purpose we performed a wound healing assay by stimulating cells with VEGF 
or PDBu, in the presence of eNOS, PKD or Akt inhibitors (Fig. 6). Cells were monitored for 
























NAME blocked migration induced by the pro-angiogenic factor VEGF and also by PDBu, 
two compounds that, as demonstrated in Figures 5A and 5B, activate endogenous PKD1/2 
and increase phosphorylation of eNOS on Ser1179. Pretreatment of BAEC with the PKD 
inhibitor Gö6976 and with Akt inhibitors significantly decreased the sealing of the wound in 
24 h (Fig. 6B and Fig. S2). These results indicate that PKD activity is required for the 
migration of endothelial cells in vitro, and also that PKD1/2 and, to a lesser extent Akt are 
involved in this process. 
Next, in order to analyze the role of PKD in eNOS Ser1179 phosphorylation BAEC 
were incubated with VEGF in the presence or absence of Gö6976 (Fig. 7A and Fig. S3). 
Inhibition of endogenous PKD1 and PKD2 significantly diminished the amount of eNOS-
pSer1179 detected in Western blot, hence underpinning the role of this kinase in eNOS 
activation in endothelial cells. However, PKD1 and PKD2 may activate eNOS and stimulate 
angiogenic processes through short and long-term mechanisms. Although it has been reported 
that PKD1 is involved in angiogenesis (Qin et al., 2006; Wong and Jin, 2005), recent results 
point toward a prominent role of PKD2 in proliferation and migration of endothelial cells 
(Hao et al., 2009). In order to determine the role of each individual isoform in eNOS 
activation in BAEC we performed gene knock-down using lentivirus that produce specific 
shRNA (short hairpin RNAs) targeted against either PKD1 or PKD2. We previously checked 
that those validated shRNAs were also effective for gene silencing of bovine PKD1 and 
PKD2 (Fig. 7B). Importantly, the knock down of PKD1 or PKD2 reduced the VEGF-
dependent eNOS phosphorylation on Ser1179 in BAEC (Fig. S4, panel A). When wound 
healing assays were performed the PKD inhibitor Gö6976 and even to a greater extent the 
specific lentivirus-mediated silencing of either PKD1 or PKD2 had a severe effect on the 
BAEC wound healing process (Fig. 7C). In addition, eNOS inhibition with L-NAME in 
PKD1- or PKD2-slienced BAEC revealed the need for ·NO in the wound healing process 
(Fig. S4, panel B). Hence, our results indicate both PKD isoforms are involved in the VEGF-
dependent eNOS activation and migration of BAEC in a wound-healing assay. This is in 
contrast with previous reports that suggested that PKD1 silencing had only a minor effect on 
HUVEC migration whereas PKD2 was the key player in this process (Hao et al., 2009). 
 
PKD regulates vascular activity in vivo 
It is generally accepted that the eNOS-generated ∙NO stimulates cGMP (cyclic Guanosine 
Monophosphate) synthesis by soluble guanylate cyclase which in turn leads to relaxation of 
























function, endothelium-dependent vasodilatation was analyzed. For that purpose, changes in 
vessel diameter in the right carotid artery of mice were measured by high-resolution 
ultrasound imaging. We have previously shown that PKD and eNOS colocalize in the 
endothelial monolayer in mouse carotid (Fig. 2C). Hence we tested the response to VEGF, a 
molecule with well-characterized vasodilatatory properties, in the presence and absence of 
PKD inhibition. VEGF injection in the mouse tail caused a rapid vasodilatation of the carotid 
artery with the maximal measured diameter increase (over 1,8-fold) observed after 2 min (Fig. 
8A). Conversely, PKD inhibition using Gö6976 for 10 min followed by the subsequent 
injection of VEGF significantly reduced vasodilatation, reaching the carotid artery a 
maximum diameter of 0.18 mm 4 min post-injection (Fig. 8B). In addition, injection of the 
PKD inhibitor Gö6976 per se had a clear vasoconstrictor effect on mice (Fig. 8B and 8C). To 
exclude potential intimal smooth muscle abnormalities, we evaluated endothelium-
independent vasorelaxation by infusing 10-7 mol/L sodium nitroprusside, showing normal 
vessel dilatation as expected (data not shown). These results indicate that the ∙NO signaling 
pathway is compromised when PKD is inhibited reflected in the vasoconstrictor effect of 
PKD inhibition and the partial loss of the VEGF-induced vasodilatatory response. Hence, 
PKD-mediated phosphorylation of eNOS might be responsible, at least in part, for the 
vasodilatory action of VEGF. 
 
Discussion 
eNOS-derived ·NO, one of the key players in vascular homeostasis, not only modulates 
blood pressure and vascular tone but also displays multiple antiatherogenic roles including 
antithrombotic, antiproliferative, anti-inflammatory and antioxidant effects (Forstermann and 
Sessa, 2010). The enzymatic levels of eNOS in the endothelium are in part regulated through 
phosphorylation on Ser, Thr and Tyr residues (Fleming, 2010; Forstermann and Sessa, 2012). 
In particular, eNOS phosphorylation on Ser1179 is without doubt the best characterized 
posttranslational modification of the enzyme, stimulating the flux of electrons within the 
reductase domain and leading to enzymatic activation. Although an atomic structure of the 
full-length reductase domain of eNOS is not available, comparison with the nNOS (neuronal 
NOS) crystal structure (Garcin et al., 2004) suggests that regulatory eNOS C-terminal tail 
very likely adopts a helical conformation, which probably fits within a negatively charged 
groove across the FAD/FMN interface, shielding the flavins from solvent. Hence, the 
activation observed upon eNOS phosphorylation on Ser1179 very likely reflects the 
























reductase domain. In addition, eNOS Ser1179 phosphorylation (very frequently accompanied 
by coordinated dephosphorylation of Thr495) diminishes Ca2+ sensitivity of the enzyme 
(Fulton et al., 1999; McCabe et al., 2000; Schneider et al., 2003). 
The use of commercially available anti-pSer1179 antibodies for eNOS has revealed that 
in unstimulated cultured endothelial cells, Ser1179 is only marginally phosphorylated. Upon 
the application of fluid shear stress (Dimmeler et al., 1999; Gallis et al., 1999), acute 
mechanical stretch (Hu et al., 2013) or UV light (Park et al., 2011), eNOS becomes rapidly 
phosphorylated on Ser1179. Likewise, treatment of endothelial monolayers with VEGF 
(Fulton et al., 1999; Michell et al., 1999), insulin (Salt et al., 2003), estrogens (Haynes et al., 
2000), endothelin-1 (Liu et al., 2003) or bradykinin (Fleming et al., 2001; Schneider et al., 
2003) leads to eNOS Ser1179 phosphorylation. To date, at least six protein kinases (Akt, 
AMPK, PKA, cGK-I/PKG, Chk1 and CaMKII) have been involved in the direct or indirect 
phosphorylation of eNOS on Ser1179, although the ones involved in each particular 
physiological response vary with the stimuli applied. For example, whereas shear stress elicits 
Ser1179 phosphorylation by PKA (Boo et al., 2002), treatment with insulin (Montagnani et 
al., 2001), estrogens (Hisamoto et al., 2001), and sphingosine-1-phosphate (Morales-Ruiz et 
al., 2001) mainly phosphorylates eNOS via Akt. On the other hand, eNOS phosphorylation on 
Ser1179 due to the treatment of endothelial cells with bradykinin, Ca2+ ionophore or 
thapsigargin is considered to be mediated through CaMKII activation (Fleming et al., 2001; 
Schneider et al., 2003). 
It has been historically accepted that VEGF-mediated eNOS Ser1179 phosphorylation 
and subsequent activation was due selectively to Akt activity. In fact, we and others have 
reported that activated Akt phosphorylates eNOS on Ser1179 (Dimmeler et al., 1999; Fulton 
et al., 1999; Michell et al., 1999). Moreover, VEGF treatment of endothelial cells results in an 
activation of Akt (Fontana et al., 2002; Fulton et al., 1999; Michell et al., 1999). However, 
expression of a dominant negative Akt mutant in BAEC only partially inhibits 
phosphorylation of eNOS Ser1179 induced by VEGF (Boo et al., 2002). The presence of 
another kinase participating in this step is inferred even more convincingly from the fact that 
isolated endothelial cells from Akt knock-out mice injected with VEGF through the jugular 
vein still show a very prominent eNOS phosphoSer1179 band in immunoblots (Schleicher et 
al., 2009). Herein we identify PKD1 and PKD2 as novel kinases able to also phosphorylate 
eNOS on Ser1179. Since the effects of VEGF on PKD activation are well established (Hao et 
al., 2009; Qin et al., 2006; Wong and Jin, 2005), it is feasible that PKD could be responsible 
























eNOS forms a cellular complex with the majority of the protein kinases known to act on 
eNOS Ser1179, such as Akt (Michell et al., 1999), CaMKII (Ching et al., 2011), Chk1 (Park 
et al., 2011) or AMPK (Hess et al., 2009). We also see a clear association between PKD1 and 
PKD2 with eNOS and show that the reductase domain of eNOS is involved in this process. 
However, eNOS phosphorylation is not required for its association with either of the PKD 
isoforms since eNOS mutants with a deleted C-terminus are still able to form a complex. 
From our studies we cannot conclude whether eNOS and PKD interact directly or need 
additional proteins. In the case of Akt, activation of the kinase by VEGF stimulation and 
subsequent phosphorylation of eNOS on Ser1179 is required for the formation of 
eNOS/Hsp90 heterocomplexes (Brouet et al., 2001; Fontana et al., 2002). Although the 
physiological meaning of the association of eNOS to the kinases that use it as substrate is 
unclear it has been suggested that, at least in the case of Akt and Chk1, chaperone Hsp90 
might perhaps function as a scaffold for the recruitment of eNOS and the kinase leading to 
eNOS activation (Fontana et al., 2002; Park et al., 2011). Interestingly, this chaperone is also 
required for VEGFR2 signaling to eNOS (Duval et al., 2007). Given the role of Hsp90 in 
VEGF and eNOS crosstalk, this chaperone could also be mediating the association between 
PKD1/PKD2 and eNOS in endothelial cells. 
Our results clearly show that eNOS is a novel PKD substrate. The consensus sequence 
of PKD protein substrates presents a hydrophobic residue such as Leu or Ile at position -5, 
together with a basic residue such as Lys or Arg at position -3 (Doppler et al., 2005; Hutti et 
al., 2004; Nishikawa et al., 1997). Comparison of this sequence with that of eNOS (Table S1) 
shows that eNOS phosphorylation site partially fail to fully meet this requirement since a 
basic Arg residue is present at the -5 position. Interestingly, the autophosphorylation motif 
located at the C-terminus of PKD1/PKD2 does not fit within the consensus phosphorylation 
sequence either since an acidic Glu residue is present at -3 position. Various amino acids 
present within the kinase recognition site of eNOS are also present in other reported PKD 
substrates, such as Thr present at -2 position in analogy to PI4KIIIb (Hausser et al., 2005) and 
HDAC5 (Vega et al., 2004), Gln at -1 position in analogy to HDAC5 (Vega et al., 2004) or 
Phe at +1 position in analogy to Kidins220 (Iglesias et al., 2000). 
Growing evidence indicates that functional activities of PKD family in the circulatory 
system and in vascular biology are of utter importance, particularly those regulating 
proliferation, migration and tubulation of endothelial cells that are crucial for angiogenesis 
(Evans and Zachary, 2011). In this regard, VEGF-dependent PKD activation is known to be 
























et al., 2009) and tumor angiogenesis (Azoitei et al., 2010). Our study shows that VEGF 
treatment activates both PKD1 and PKD2 in BAEC, a result that is in accordance to studies 
performed in other endothelial cells (Evans et al., 2008; Evans and Zachary, 2011; Ha et al., 
2008; Ha and Jin, 2009; Qin et al., 2006). We also find that pharmacological inhibition of 
PKD or specific silencing of PKD1 or PKD2 hampers BAEC migration in wound healing, a 
process known to be dependent on eNOS.  
The role of endothelial PKD isoforms in vascularization of tumours is becoming more 
evident, since recent data indicate that the abnormal proliferation of HUVECs observed in the 
presence of dimethylhydrazine is dependent on PKD1. Downregulation of this kinase using 
siRNA inhibited abnormal proliferation and formation of vascular neoplasms (Nam et al., 
2012). PKD is known to regulate cell migration through different mechanisms, being the one 
associated to its role in the regulation of actin dynamics very well documented (Olayioye et 
al., 2013). Indeed, many PKD substrates regulate cellular migration through this mechanism, 
resulting their phosphorylation in inhibition or enhancement of migration (Olayioye et al., 
2013).  
Here, we discover an additional mechanism by which PKD can control endothelial cell 
migration in response to VEGF by having a direct action on eNOS phosphorylation and 
activation. Whether all these mechanisms are interconnected or how important might be the 
contribution of each of them to endothelial function remains to be determined. In summary, 
our findings reinforce the pivotal role played by PKD in endothelial cell biology, adding to 
the list of PKD functions its ability to directly phosphorylate and activate eNOS, a critical 

























Materials and Methods 
 
Materials, chemicals and antibodies 
VEGF, Phorbol-12, 13-dibutyrate (PDBu), Gö69761, Tricibirine, Akt 1/2 kinase inhibitor, L-
NGnitroarginine methyl ester (L-NAME), 4,5- Diaminofluorescein diacetate (DAF2-DA), 
Protein A-Sepharose, 2´,5´-ADP-Sepharose, adenosine 2′(3′)-monophosphate mixed isomers, 
(6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) and ATP were from Sigma Co. (St. 
Louis, MO, USA). Ni-NTA resin was from Qiagen (Chatsworth, CA, USA) and Glutathione 
Sepharose was from Amersham (Buckimhamshire, UK). L-Arginine was purchased from 
Calbiochem (Merck Millipore, Darmstadt, Germany). [14C]-L-Arg was from GE Healthcare 
(Uppsala, Sweden). Phosphatase inhibitors PhosSTOP were from Roche. Mouse monoclonal 
antibodies anti-eNOS and anti-eNOS-phospho-Ser1179 (Ser1177 in human eNOS and Ser1179 in 
bovine eNOS) were from BD Transduction laboratories. Mouse monoclonal antibodies 
recognizing total VASP and PKD2, and rabbit polyclonal antibodies anti-VASP-phospho-
Ser239, anti-PKCμ (recognizing total PKD1/2) and anti-PKCμ-phospho-Ser910 were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). We produced antibodies against eNOS 
and GFP immunizing rabbits with purified bovine eNOS or GFP. Anti-tubulin monoclonal 
antibody, horseradish peroxidase conjugated anti-rabbit and anti-mouse secondary antibodies 
and the fluorescent secondary antibodies labeled with Cy2 or Cy3 were from Sigma.  
 
Cloning and expression of eNOS 
The molecular cloning, recombinant expression and purification of eNOS has been previously 
described (Rodriguez-Crespo et al., 1996; Rodriguez-Crespo et al., 1997; Rodriguez-Crespo 
et al., 1999).  
 
Cloning and expression of recombinant active catalytic domain of PKD1 fused to GST 
The C-terminal region of PKD1 (Ser558-Leu918; PKD1cat) containing the full-length 
catalytic domain was amplified with pBS-PKD1 as template. The PCR product was cloned in 
pDONR201 by a recombination reaction with BP clonase (GATEWAY system, Invitrogen-
Life Technologies; Carlsbad, CA, USA), to generate the construct pENTR-PKD1cat. After 
automated sequencing, PKD1cat was subcloned in pDEST15 using LR clonase. This vector 
for prokaryotic expression generates PKD1cat fussed to glutathione S transferase (GST; GST-
























methods and stored at -20°C. This protein is constitutively active since it lacks the regulatory 
autoinhibitory domain.  
 
Cell culture and transfection, immunoprecipitation, immunofluorescence, confocal 
microscopy, and tissue immunostaining 
We followed the procedures previously reported (Navarro-Lerida et al., 2006; Navarro-Lerida 
et al., 2007).  
 
[14C]-L-Arginine to [14C]-L-Citrulline conversion assay  
We followed the procedure previously reported (Navarro-Lerida et al., 2004). Briefly, COS-7 
cells were transfected with the desired construct and 48 h after transfection cells were 
harvested, sonicated for 5 seconds and separation of [14C]-L-Arg and [14C]-L-Cit was 
performed in a Dowex resin. We used approximately 1 µCi of [14C]-L-Arg per condition.  
 
Micro-ultrasound Imaging 
We followed the procedures already published by our group (Herranz et al., 2012). Flow 
dilatation was measured before and after infusion of VEGF (30 µL of a 10 µg/mL solution in 
water), the PKD inhibitor Gö6976 (30 µL of a 225 µg/mL solution in DMSO), or both 
substances. Readings were taken immediately after injection (0 min; t 0) and after 1, 2, 4 and 
10 min. To test endothelium-independent vasorelaxation, sodium nitroprusside was infused at 
10-7 mol/L (30µL) and recordings taken as above. Each condition was tested in at least four 
animals. Image analyses were performed off-line from recorded loops using the automated 
system software provided by the manufacturer (Visualsonics). The study was conducted 
following the guidelines of the Spanish Animal Care and Use Committee, according to the 
guidelines for ethical care of experimental animals of the European Union (2010/63/EU). This 
study conforms to the Guide for the Care and Use of Laboratory Animals published by the 
U.S.National Institute of Health (NIH Publication No. 85–23, revised 1996). 
 
Phosphorylation of eNOS by active catalytic domain of PKD1 (GST-PKD1cat) 
Phosphorylation was determined performing in vitro kinase assay. Briefly, purified full-length 
eNOS and GST-PKD1cat were mixed in kinase buffer (10 mM Tris-HCl, pH 7.5, 5 mM 
MgCl2 and 1 mM dithiothreitol), and subjected to an in vitro kinase assay for 1 h at RT in the 
presence or absence of 100 μM final concentration of ATP. Samples were analyzed by mass 

























Identification of PKD1-phosphorylated residue in eNOS by mass spectrometry or 
MALDI TOF/TOF 
In vitro phosphorylated eNOS was digested with trypsin and analyzed by HPLC followed by 
MALDI TOF/TOF and peptide fragmentation and de novo sequencing in the Proteomic 
Studies Unit (Unidad de Proteómica; Facultad de Farmacia Parque Científico de Madrid, 
UCM, Madrid, Spain).  
 
Wound-healing assays 
BAEC migration was determined using a scratch wound assay as previously reported 
(Borniquel et al., 2010; Lopez-Rivera et al., 2005). 
 
Production of lentiviruses 
Validated shRNA cloned in pLKO.1 vector, against human PKD1 (two constructs: 
TRCN0000195251 and TRCN0000002124), named shPKD1-A and B, respectively, and 
against human PKD2 (TRCN0000001948 and TRCN0000001950) named shPKD2-A´ and B´ 
were purchased from Sigma (MISSION® shRNA lentiviral plasmids). Lentiviral production 
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Legends to Figures 
Fig. 1. Identification of Ser1179 in bovine eNOS as the site targeted by PKD1 
phosphorylation. Purified bovine eNOS (accession number P29473) was phosphorylated by 
purified active catalytic domain of PKD1 fused to GST (PKD1-cat active) in an in vitro 
kinase assay using ATP and Mg2+. (A) After the phosphorylation reaction, the sample was 
completely digested with trypsin and the resulting peptides analyzed by HPLC coupled to 
MALDI-TOF/TOF. The MS/MS spectra of the tryptic eNOS peptide 1177TQpSFSLQER1185 
(Mass, 1174,502 Da) is shown. Nearly complete b-ion (N-terminal fragmentation) and y-ion 
(C-terminal fragmentation) series are visible, and fragmentation of the precursor 
unequivocally reveals that Ser1179 is the phosphorylation site. The typical generation of 
dehydroalanine from phosphoserine through loss of phosphate during analysis is observed by 
a -98 Da shift of b- and y- ions. No other phosphopeptides could be detected among the over 
200 peptides resolved by HPLC coupled to MALDI-TOF/TOF analysis. (B) Purified eNOS 
phosphorylation by PKD1 at Ser1179 was detected by immunoblot using a specific antibody 
recognizing phospho-Ser1179 within eNOS. PKD activity was detected using the phospho-
specific antibody recognizing autophosphorylated Ser916. PKD and eNOS immunoblots are 
also shown. 
 
Fig. 2. PKD1 and PKD2 are expressed in endothelial cells and their overexpression in 
BAEC enhances eNOS phosphorylation on Ser1179. (A) BAEC were transfected with 
either GFP or GFP-tagged wild-type PKD1 or PKD2. One day after transfection the medium 
was replaced with fresh serum-free medium with extra L-Arg (5 mM) and BH4 (15 μM). 
Cellular lysates were analyzed by immunoblot to detect eNOS phosphorylation on Ser1179. 
PKD1 or PKD2 activity was also determined using phospho-Ser916 antibody (Matthews et 
al., 2000). Detection of phosphorylated VASP (VASP-pSer239) as a doublet of 45 kDa and 
50 kDa was used as a measurement of downstream signaling activated by ·NO production. 
Levels of total endogenous eNOS and VASP, or transfected PKD are also shown. Tubulin 
immunoblot was used as protein loading control. Data are representative of three independent 
experiments. (B) Immunoblot analysis of endogenous levels of PKD1 and PKD2 in BAEC, 
using an antibody that recognizes both isoforms (PKDt) or another antibody detecting 
specifically PKD2. (C) Endogenous PKD expression in endothelium. Confocal microscopy 
image of a transverse section 20 μm thick of a mouse carotid artery immunostained for eNOS 
























endothelium and vascular smooth muscle cells. Endothelial cells showed also a high staining 
for eNOS (red). Nuclei were stained with DAPI (blue). Scale bar: 50 μm. 
 
Fig. 3. PKD activity regulates eNOS Ser1179 phosphorylation and activation of the 
synthesis of ·NO. (A) HEK293T cells were cotransfected with either GFP vector (-), wild-type 
GFP-PKD1 (PKD1wt) or wild-type GFP-PKD2 (PKD2wt), and full-length wild-type eNOS or 
its non phosphorylatable mutant eNOS-Ser1179Ala (eNOSSA). (B) HEK293T cells were 
cotransfected with either GFP vector alone (-), wild-type GFP-PKD1 (PKD1wt), constitutively 
active GFP-PKD1 (PKD1ca) or kinase inactive mutant of PKD1 (PKD1ki) together with full-
length wild-type eNOS or its non phosphorylatable mutant eNOS-Ser1179Ala (eNOSSA). In 
both panels A and B, 24 h after transfection, the medium was replaced with serum-free medium 
and 24 h later cells were lysed. Total lysates were analyzed by immunoblot. Panels on the right 
represent the quantification of the immunoblot signals corresponding to the ratio eNOS-
pSer1179/eNOS, and expressed relative to the value obtained in cells transfected with eNOS 
plus GFP (arbitrarily assigned a value of 1). Data are mean ± s.e.m. for three independent 
determinations, *P<0.05. (C) COS-7 cells were transfected with empty pcDNA3 plasmid, full-
length wild-type eNOS or the non-phosphorylatable mutant eNOS-Ser1179Ala (eNOSSA) 
together or not with PKD1wt. In a different well, iNOS was transfected, which served as a 
measure of large amounts of cellular released ·NO. One day post-transfection the medium was 
replaced with fresh serum-free medium with additional L-Arg (5 mM) and BH4 (15 μM) and 
where indicated 48 h after transfection cells were treated with PDBu (1 µM) or L-NAME (500 
µM) before washing with medium and incubated with the fluorescent ·NO sensor DAF2-DA 
(25 µM) for 4h. Subsequently, the monolayer was extensively washed with medium and the 
fluorescence was detected between 505 and 525 nm using an excitation wavelength of 488 nm. 
A minimum of four large monolayer fields of over 400 cells were captured. Fluorescence was 
quantified through pixel to pixel intensity determination and the resulting fluorescence 
corresponding to cells transfected with the empty vector (DAF) was subtracted from each 
condition (plot). Data are mean ± s.d. for four determinations. *P<0.05 in relation to cells 
transfected with the empty vector (DAF). (D) COS-7 cells were cotransfected with either GFP 
vector alone (-), GFP-tagged wild-type PKD1, PKD2 or constitutively active PKD1 (PKD1ca) 
together with full-length wild-type eNOS. In a different well, iNOS was transfected, which 
served as a measure of large amounts of [14C]-L-Cit generation. One day post-transfection the 
medium was replaced with fresh serum-free medium and when indicated cells were treated 
























and conversion of [14C]-L-Arg to [14C]-L-Cit was analyzed as previously described (Navarro-
Lerida et al., 2004) using 1 µCi for each condition. The resulting [14C]-L-Cit measurement 
obtained for non-transfected cells was subtracted from each condition and the [14C]-L-Arg to 
[14C]-L-Cit conversion (%) was referred to cells transfected with iNOS to which a 100% 
conversion was assigned. Data are mean ± s.e.m. for 3 independent experiments. *P<0.05 in 
relation to cells transfected only with eNOS. 
 
Fig. 4. PKD1 or PKD2 and eNOS form a complex in transfected cells albeit 
phosphorylation on eNOS Ser1179 is not necessary for this association. (A) HEK293T cells 
were cotransfected with either GFP vector alone (-), wild-type GFP-PKD1 (PKD1) or wild-
type GFP-PKD2 (PKD2), together with full-length wild-type eNOS or with an eNOS construct 
that lacks the C-terminal tail, eNOSΔ27 (aa 1-1178 hence lacking the phosphorylatable 
Ser1179). 24 h after transfection medium was replaced with serum-free medium and one day 
later cells were lysed and immunoprecipitated with anti-GFP antibody (Ip: GFP). The presence 
of eNOS and PKD in immunocomplexes was analyzed by immunoblot using anti-eNOS and 
anti-GFP antibodies, respectively. Levels of eNOS-pSer1179, total eNOS, PKDs, GFP alone 
and tubulin in total lysates are also shown. (B) HEK293T cells were cotransfected with either 
GFP vector alone (-), wild-type GFP-PKD1 (PKD1wt), constitutively active GFP-PKD1 
(PKD1ca), or mutants lacking the PH domain (PKD1ΔPH) or the cysteine-rich domain 
(PKD1ΔCRD) together with full-length wild-type eNOS. 24 h after transfection the medium was 
replaced with serum-free medium and one day later cells were treated (+) or not (-) with 1 μM 
PDBu for 15 min. Cell lysates were immunoprecipitated and analyzed together with total 
lysates as described for panel A. (C) HEK293T cells were cotransfected with either pcDNA3 
vector alone or wild-type PKD1 together with different eNOS constructs: full-length eNOS 
(F.L. eNOS), the eNOSΔ27 mutant, the isolated eNOS NADPH domain (aa 988-1205), the 
eNOS heme-oxygenase domain (HEME, aa 1-521), and the empty vector (empty). 24 h after 
transfection the medium was replaced with serum-free medium and one day later cells were 
treated (+) or not (-) with 1 μM PDBu for 15 min, followed by lysis and immunoprecipitation 
with anti-eNOS antibody (Ip: eNOS). Cell lysates and immunocomplexes were analyzed as 
described for panel A. Please note that the commercial antibody recognizing total PKD has 
been elicited using the C-terminus of PKD (including the phosphorylatable Ser916) as epitope 
and hence it recognizes with less efficiency phosphorylated than non-phosphorylated PKD 

























Fig. 5. PDBu and VEGF stimulation of BAEC results in PKD activation and eNOS 
phosphorylation, and the subcellular redistribution of both proteins. (A-C) BAEC were 
seeded and 24 h later the medium was replaced with serum-free medium. The following day, 
cells were treated with PDBu (1 μM) for 15 min (panel A), VEGF (10 ng/ml) for 30 min (Panel 
B) or with VEGF (10 ng/ml) at different times (Panel C). Total lysates were analyzed by 
immunoblot for eNOS-pSer1179, eNOS, PKD-pSer916, PKD1 and tubulin. Graphs represent 
the quantification of the immunoblot signals corresponding to the ratio PKD-pSer916/PKD1 or 
eNOS-pSer1179/eNOS, and expressed relative to the value obtained at time 0 min, that 
represents basal phosphorylation. Data are mean ± s.e.m. for three independent determinations, 
*P<0.05 versus untreated cells. (D) Treatment of BAEC with VEGF causes a fast redistribution 
of endogenous eNOS and transfected PKD1. BAEC seeded on coverslips were transfected with 
wild-type GFP-PKD1 (PKD1wt). 24 h later medium was replaced with serum-free medium and 
48 h post-transfection cells were treated or not with VEGF (10 ng/ml) for 15 min. The 
subcellular location of eNOS (red) and PKD (green) was analyzed by confocal microscopy. 
Merge images are also shown. Nuclei were stained with DAPI. Scale bar: 20 µm.  
 
Fig. 6. Effects of eNOS, PKD and Akt inhibition in BAEC wound-healing. Migration of 
BAEC was determined using a scratch wound assay. BAEC were seeded and 24 h later the 
medium of confluent monolayers was replaced with serum-free medium. The following day, 
medium was again replaced with fresh serum-free medium with extra L-Arg (5 mM) and BH4 
(15 μM) and cells were pre-treated or not with (Panel A) the eNOS inhibitor L-NAME (500 
μM) or (Panel B) the PKD inhibitor Gö6976 (20 μM), or two Akt inhibitors: Akt 1/2 inhibitor 
(20 μM) or Tricibirine (1 μM) for 1 hour before challenging cells with VEGF (10 ng/ml) or 
PDBu (1 μM) in the presence of the inhibitors. Each cell monolayer was scraped with a 10 μl 
pipette tip to create a cell-free zone. BAEC migration was quantified by taking pictures each 
30 min during 24 h and by assessing the percentage of area recovery as previously described 
(Reinhart-King, 2008). A minimum of three independent wound-healing experiments were 
performed for each condition. Graphs on the right represent the area recovery (%). Data are 
mean ± s.d. for three determinations. *P<0.05 versus cells not incubated with L-NAME (A) 
or cells not treated with kinase inhibitors (B). 
 
Fig. 7. Gene silencing of PKD1 or PKD2 severely affect VEGF-induced wound-healing 
in BAEC. (A) BAEC were seeded and 24 h later the medium was replaced with serum-free 
























where indicated, stimulated with VEGF (10 ng/ml) for 30 min. Total lysates were analyzed by 
immunoblot for eNOS-pSer1179, eNOS and tubulin. (B) Lentiviral particles carrying empty 
pLKO.1 vector or commercially available validated shRNAs against PKD1 (lanes A and B) or 
PKD2 (lanes A´ and B´) cloned in pLKO.1 vector were used to transduce BAEC. Cells were 
collected at least 72 h later and total protein extracts were probed by Western blotting with 
antibodies designated. Western blots show that the shRNAs effectively knocked-down PKD1 
(upper panel) or PKD2 (lower panel) expression in BAEC. (C) VEGF-mediated endothelial 
cell migration was assayed after incubation with the PKD inhibitor Gö6976 (20 µM) or after 
gene silencing of PKD1 or PKD2 using lentiviruses. Migration of BAEC stimulated with 
VEGF (10 ng/ml) was determined using a scratch wound assay. Data are mean ± s.d. for three 
determinations. *P<0.05 versus cells transduced with control lentivirus. 
 
Fig. 8. VEGF-mediated vasodilatation of mouse carotid artery is compromised by 
inhibition of PKD. High-frequency ultrasound measurement of changes in carotid artery 
diameter, in response to 30 μl-intravenous tail injection of (A) 10 μg/ml VEGF or (B) 225 
μg/ml PKD inhibitor Gö6976 followed by VEGF. Vasodilatation is expressed as the carotid 
diameter reading (4 mice/group, mean ± s.d.). (C) Real time non-invasive anatomical location 
of the mouse left common carotid artery by B-mode high frequency ultrasound (left panel, 
upper figure), and visualization of blood flow by color doppler ultrasound (left panel, lower 
figure). Real time cine-loop recording to detect internal carotid lumen diameter by M-mode 
high frequency ultrasound of the same vessel as before. The micrographs represent recording 
sections corresponding with three full heart cycles. Vertical lines represent internal lumen 
systolic carotid diameter of arteries corresponding to mice injected with VEGF for 5 min 
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